Active Ingredient(s):Ofatumumab FDA Approved: * October 26, 2009 Pharm Company: *GLAXO GRP LTD Category:Cancer
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
The most common side effects for o...
* May have multiple approval dates, manufacturers, or labelers.